Whereas CAR-T–associated CRS is typically driven by rapid T-cell proliferation and high levels of interleukin-6 and interferon-gamma [8, 25], chemotherapy-induced antigen release may act as an amplifier, precipitating delayed CRS. The gene discussed is IFNG; the disease is congenital rubella syndrome.